Monday, June 3, 2013

NEWS FROM ASCO

*Avastin added to progression free and overall survival achieved by chemotherapy in cervical cancers in recurrent and metastatic settings (17 Vs 13.3 months).  But it did fail to improve anything in Glioblastoma  when given in first line ,

*Sorafenib (NEXAVAR)Showed Benefit in Radioactive Iodine-Refractory Differentiated Thyroid Cancer, as reported by Medical News Today, 

"The researchers reported that:
  • 12% of the sorafenib patients experienced tumor shrinkage
  • 0.5% of those on placebo experienced tumor shrinkage
  • 42% of patients in the sorafenib group had stable disease after 6 months
  • 33% of patients in the placebo group had stable disease after 6 months
  • PFS (progression-free survival) in the sorafenib arm was 10.8 months
  • PFS among the placebo patients was 5.8 months
  • In this cross-over trial, 70% of the placebo patients switched over to sorafenib"

*Extending Tamoxifen to 10years is better than 5 years
ASCO News:

"
Compared with 5 years of tamoxifen, a 10-year regimen was associated with a significant 15% reduction in the risk of recurrence (relative risk, 0.85; p = 0.003) and a significant 25% reduction in the risk of breast cancer mortality starting at year 10 (relative risk, 0.75; p = 0.007). These findings aligned closely with those from the recently published ATLAS trial."






No comments: